IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Insight Molecular Diagnostics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.89−0.12 (-3.99%)
Close on Oct 19, 2026
- Market cap
- $106.21M
- P/E (TTM)
- –
- Dividend yield
- –
Insight Molecular Diagnostics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Market Cap | $94.57M | $197.05M |
| Enterprise Value | $76.82M | $106.56M |
| PS Ratio | 56.63 | 3.93 |
Enterprise value
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| EV / Sales | 46.00 | 2.69 |
Income (trailing twelve months)
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Revenue | $1.67M | $57.94M |
| Gross Profit | $807.00K | $90.47M |
| Operating Income | -$50.30M | -$21.44M |
| Net Income | -$49.36M | -$22.46M |
| EBITDA | -$47.86M | -$16.91M |
| EPS (Diluted) | -$1.49 | -$0.83 |
Margins
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Gross Margin | 48.3% | 52.3% |
| Operating Margin | -3011.9% | -44.5% |
| Profit Margin | -2955.6% | -39.2% |
| EBITDA Margin | -2865.6% | -31.3% |
| FCF Margin | -1856.2% | -8.85% |
Returns
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -123.5% | -41.0% |
| Return on Capital Employed (ROCE) | -262.6% | -37.8% |
Growth
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -60.8% | 6.01% |
| Revenue Growth (3Y CAGR) | 61.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 27.2% | 6.42% |
Balance sheet
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $17.76M | $62.42M |
| Net Cash (Debt) | $17.76M | $15.68M |
| Net Cash Per Share | $0.54 | $0.65 |
| Equity (Book Value) | -$21.30M | $48.79M |
| Book Value Per Share | -$0.65 | $1.36 |
| Tangible Book Value | -$21.30M | $23.06M |
| Working Capital | $10.26M | $75.77M |
Financial position
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Current Ratio | 2.00 | 3.30 |
| Quick Ratio | 1.74 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Operating Cash Flow | -$27.08M | -$12.35M |
| Capital Expenditures | -$3.92M | -$1.06M |
| Free Cash Flow | -$31.00M | -$20.28M |
| FCF Per Share | -$0.95 | -$0.41 |
Efficiency
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Asset Turnover | 0.04 | 0.38 |
| Inventory Turnover | 1.92 | 2.67 |
| Revenue Per Employee | $28.79K | $398.96K |
| Profits Per Employee | -$851.02K | -$732.08K |
| Employee Count | 58 | 73 |
Dividends and yields
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Earnings Yield | -52.2% | -21.2% |
| FCF Yield | -32.8% | -7.64% |
| Buyback Yield | -27.5% | -0.58% |
| Shareholder Yield | -27.5% | 0.00% |
Shares
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Shares Outstanding | 32,724,300 | 59,128,900 |
| Shares Change (YoY) | 52.4% | 11.1% |
| Shares Change (QoQ) | 1.04% | 0.54% |
| Float | 6,025,190 | 48,744,500 |
| Shares Held by Insiders | 81.6% | 11.8% |
| Shares Held by Institutions | 56.4% | 59.4% |
Taxes
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Insight Molecular Diagnostics | Industry median |
|---|---|---|
| Altman Z-Score | -23.84 | 0.10 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -7.92 | -2.62 |
Calculated by StockData from Insight Molecular Diagnostics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.